Drug Profile
Influenza A virus vaccine - Mucosis
Alternative Names: FluGEM; Mimopath®-based influenza vaccine - MucosisLatest Information Update: 24 Jan 2018
Price :
$50
*
At a glance
- Originator Mucosis
- Developer Centre for Human Drug Research; Mucosis
- Class Influenza A vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 21 Mar 2016 Phase I development is underway in the Netherlands
- 10 May 2012 Final immunogenicity and adverse events data from a phase I trial in Influenza virus infection prevention released by Mucosis
- 10 May 2012 Mucosis and the Centre for Human Drug Research complete a phase I safety and immunogenicity trial in Influenza virus infections prevention in the Netherlands